FilingReader Intelligence
Yipinhong subsidiary obtains drug registration certificate
July 31, 2025 at 04:12 AM UTC•By FilingReader AI
Guangzhou Yipinhong Pharmaceutical, a wholly-owned subsidiary of Yipinhong Pharmaceutical Group, has obtained a drug registration certificate for Compound Polyethylene Glycol Electrolyte Powder from the National Medical Products Administration.
Sales of the product in Chinese urban and county-level public hospitals reached approximately RMB 21,959 in 2024. The approval expands Yipinhong's product pipeline and market competitiveness.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300723•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Yipinhong Pharmaceutical publishes news
Free account required • Unsubscribe anytime